NCT03370172: A reported trial by Baxalta now part of Shire
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03370172 |
|---|---|
| Title | A Global, Open-Label, Multicenter, Phase 1/2 Study of the Safety and Dose Escalation of BAX 888, an Adeno-Associated Virus Serotype 8 (AAV8) Vector Expressing B-Domain Deleted Factor VIII (BDD-FVIII) in Severe Hemophilia A Subjects Administered a Single Intravenous Infusion |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Feb. 27, 2018 |
| Completion date | July 9, 2024 |
| Required reporting date | July 9, 2025, midnight |
| Actual reporting date | July 9, 2025 |
| Date last checked at ClinicalTrials.gov | April 29, 2026 |
| Days late | None |